» Articles » PMID: 34135895

Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients

Abstract

The reason why most individuals with COVID-19 have relatively limited symptoms while other develop respiratory distress with life-threatening complications remains unknown. Increasing evidence suggests that COVID-19 associated adverse outcomes mainly rely on dysregulated immunity. Here, we compared transcriptomic profiles of blood cells from 103 patients with different severity levels of COVID-19 with that of 27 healthy and 22 influenza-infected individuals. Data provided a complete overview of SARS-CoV-2-induced immune signature, including a dramatic defect in IFN responses, a reduction of toxicity-related molecules in NK cells, an increased degranulation of neutrophils, a dysregulation of T cells, a dramatic increase in B cell function and immunoglobulin production, as well as an important over-expression of genes involved in metabolism and cell cycle in patients infected with SARS-CoV-2 compared to those infected with influenza viruses. These features also differed according to COVID-19 severity. Overall and specific gene expression patterns across groups can be visualized on an interactive website (https://bix.unil.ch/covid/). Collectively, these transcriptomic host responses to SARS-CoV-2 infection are discussed in the context of current studies, thereby improving our understanding of COVID-19 pathogenesis and shaping the severity level of COVID-19.

Citing Articles

An ultra-early, transient interferon-associated innate immune response associates with protection from SARS-CoV-2 infection despite exposure.

Fenn J, Madon K, Conibear E, Derelle R, Nevin S, Kundu R EBioMedicine. 2024; 111():105475.

PMID: 39667271 PMC: 11697275. DOI: 10.1016/j.ebiom.2024.105475.


Novel Core Gene Signature Associated with Inflammation-to-Metaplasia Transition in Influenza A Virus-Infected Lungs.

Savin I, Senkova A, Goncharova E, Zenkova M, Markov A Int J Mol Sci. 2024; 25(22).

PMID: 39596028 PMC: 11594146. DOI: 10.3390/ijms252211958.


Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease.

Drury R, Camara S, Chelysheva I, Bibi S, Sanders K, Felle S Nat Commun. 2024; 15(1):3402.

PMID: 38649734 PMC: 11035709. DOI: 10.1038/s41467-024-47463-6.


Hypoxia and Activation of Neutrophil Degranulation-Related Genes in the Peripheral Blood of COVID-19 Patients.

Lei H Viruses. 2024; 16(2).

PMID: 38399976 PMC: 10891603. DOI: 10.3390/v16020201.


Global analysis of the abundance of AU-rich mRNAs in response to glucocorticoid treatment.

Muazzen Z, Moghrabi W, Bakheet T, Mahmoud L, Al-Saif M, Khabar K Sci Rep. 2024; 14(1):913.

PMID: 38195703 PMC: 10776588. DOI: 10.1038/s41598-024-51301-6.


References
1.
Kindler E, Thiel V, Weber F . Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. Adv Virus Res. 2016; 96:219-243. PMC: 7112302. DOI: 10.1016/bs.aivir.2016.08.006. View

2.
Josset L, Menachery V, Gralinski L, Agnihothram S, Sova P, Carter V . Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio. 2013; 4(3):e00165-13. PMC: 3663187. DOI: 10.1128/mBio.00165-13. View

3.
Fan Y, Sanyal S, Bruzzone R . Breaking Bad: How Viruses Subvert the Cell Cycle. Front Cell Infect Microbiol. 2018; 8:396. PMC: 6252338. DOI: 10.3389/fcimb.2018.00396. View

4.
Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

5.
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View